Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma

Laboratory Investigation

Volumn 85, Issue 7, 2005, Pages 874-884

  Jeon, Yoon Kyung ^a   Kim, Heejung ^a   Park, Soo Oh ^a   Choi, Hye Young ^a   Kim, Young A ^b   Park, Sung Shin ^b   Kim, Ji Eun ^b   Kim, Yong Nyun ^a   Kim, Chul Woo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

Author keywords

Apoptosis; Cycloheximide; DAP kinase; EBV; Fas; FLIP; NK T cell lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; CASPASE 8; CYCLOHEXIMIDE; DEATH ASSOCIATED PROTEIN KINASE; ETOPOSIDE; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; PROTEIN BID;

ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL PROLIFERATION; CELL SURVIVAL; CYCLOHEXIMIDE; DOWN-REGULATION; ENZYME ACTIVATION; ETOPOSIDE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; PROTEIN SYNTHESIS INHIBITORS;

EID: 22544466962     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700291     Document Type: Article

References (43)

1. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (Apo-1/Fas) signaling pathways. EMBO J 1998;7: 1675-1687.
2. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:312-316.
3. French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002;12:51-55.
4. Shen L, Liang ACT, Lu L, et al. Frequent deletion of Fas gene sequence encoding death and transmembrane domains in nasal natural killer/T cell lymphoma. Am J Pathol 2002;161:2123-2131.
5. Takakuwa T, Dong Z, Nakatsuka S, et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 2002;21:4702-4705.
6. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-2357.
7. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
8. Snow AL, Chen LJ, Nepomuceno RR, et al. Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphoma is due to defects in the proximal Fas signaling pathway. J Immunol 2001;167:5404-5411.
9. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388: 190-195.
10. Krueger A, Baumann S, Krammer PH, et al. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247-8254.
11. Tran SEF, Meinander A, Holmström TH, et al. Heat stress downregulated FLIP and sensitizes cells to Fas receptor-mediated apoptosis. Cell Death Differ 2003; 10:1137-1147.
12. Okano H, Shiraki K, Inoue H, et al. Cellular FLICE/ caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 2003;83:1033-1043.
13. Kinoshita H, Yoshikawa H, Shiki K, et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/ CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000;88:986-991.
14. Mathas SM, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199:1041-1052.
15. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-670.
16. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16: 70-77.
17. Hammerschimidt W, Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 1989;340:393-397.
18. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-840.
19. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA 1997; 94:1447-1452.
20. Roberts ML, Cooper NR. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998;240:93-99.
21. Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxyterminal cytoplasmic domain. Oncogene 1995;10: 549-560.
22. Dawson CW, Tramountanis G, Eliopoulos AG, et al. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003;278:3694-3704.
23. Kagami Y, Nakamura S, Suzuki R, et al. Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3ε+, CD56+ phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998;103:669-677.
24. Tsuchiyama J, Yoshino T, Mori M, et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998;92:1374-1383.
25. Cohen O, Inbal B, Kissil JL, et al. DAP-kinase participated in TNF-α- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999;146:141-148.
26. Nakatsuka S, Takakuwa T, Tomita Y, et al. Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Sci 2003;94:87-91.
27. Martin SJ, Green DR. Protease activation during apoptosis: death by thousand cuts? Cell 1995;82: 349-352.
28. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Cancer 1998;83:806-812.
29. Ng CS, Lo ST, Chan JK. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. Hum Pathol 1999;30:48-53.
30. Medema JP, de Jong J, van Hall T, et al. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999;190:1033-1038.
31. Djerbi M, Screpanti V, Catrina AI, et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999;190:1025-1032.
32. Ryu BK, Lee MG, Chi SG, et al. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 2001; 194:15-19.
33. Bullani RR, Huard B, Viard-Leveugle I, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 2001;117:360-364.
34. Thomas RK, Kallenborn A, Wickenhauser C, et al. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160:1521-1528.
35. Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood 1999;94:1727-1737.
36. Suhara T, Mano T, Oliveria BE, et al. Phosphatidylinositol 3-Kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein. Circ Res 2001;89: 13-19.
37. Barkett M, Gilmore TD. Control of apoptosis by Rel/ NF-kappaB transcription factors. Oncogene 1999;18: 6910-6924.
38. Panka DJ, Mano T, Suhara T, et al. Phosphatidylinositol 3-kinase/Akt actively regulates c-FLIP expression in tumor cells. J Biol Chem 2001;276:6893-6896.
39. Cahir-McFarland ED, Carter K, Rosenwald A, et al. Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004;78:4108-4119.
40. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997;390:180-184.
41. Bidère N, Briet M, Dürrbach A, et al. Selective inhibition of dipeptidyl peptidase I, not caspases, prevents the partial processing of procaspase-3 in CD3-activated human CD8+ T lymphocytes. J Biol Chem 2002;277:32339-32347.
42. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-2223.
43. Kamradt MC, Chen F, Cryns V. The small heat shock protein (B-Crystallin) negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 2001;276:16059-16063.